$2.05
0.49%
Nasdaq, Apr 21, 08:46 pm CET
ISIN
US00972D1054
Symbol
AKBA
Sector
Industry

Akebia Therapeutics, Inc. Stock price

$2.06
-0.34 14.17% 1M
+0.73 54.89% 6M
+0.16 8.42% YTD
+0.67 48.20% 1Y
+1.59 337.55% 3Y
-5.40 72.39% 5Y
-6.25 75.21% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.16 8.42%
ISIN
US00972D1054
Symbol
AKBA
Sector
Industry

Key metrics

Market capitalization $538.14m
Enterprise Value $680.92m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.25
P/S ratio (TTM) P/S ratio 3.36
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -17.75%
Revenue (TTM) Revenue $160.18m
EBIT (operating result TTM) EBIT $-50.42m
Free Cash Flow (TTM) Free Cash Flow $-40.69m
Cash position $51.87m
EPS (TTM) EPS $-0.33
P/E forward negative
P/S forward 2.80
EV/Sales forward 3.54
Short interest 6.70%
Show more

Is Akebia Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Akebia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Akebia Therapeutics, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Akebia Therapeutics, Inc. forecast:

Buy
100%

Financial data from Akebia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
160 160
18% 18%
100%
- Direct Costs 69 69
8% 8%
43%
91 91
24% 24%
57%
- Selling and Administrative Expenses 68 68
2% 2%
42%
- Research and Development Expense 32 32
48% 48%
20%
-8.71 -8.71
0% 0%
-5%
- Depreciation and Amortization 42 42
14% 14%
26%
EBIT (Operating Income) EBIT -50 -50
11% 11%
-31%
Net Profit -69 -69
35% 35%
-43%

In millions USD.

Don't miss a Thing! We will send you all news about Akebia Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akebia Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
18 days ago
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to appr...
Neutral
GlobeNewsWire
19 days ago
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia's common stock on March 31, 2025. The options were granted as an inducement material to each employe...
Neutral
GlobeNewsWire
27 days ago
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025.
More Akebia Therapeutics, Inc. News

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO John Butler
Employees 181
Founded 2007
Website www.akebia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today